BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21860256)

  • 21. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults.
    Lazarus R; Clutterbuck E; Yu LM; Bowman J; Bateman EA; Diggle L; Angus B; Peto TE; Beverley PC; Mant D; Pollard AJ
    Clin Infect Dis; 2011 Mar; 52(6):736-42. PubMed ID: 21367726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
    Kieninger DM; Kueper K; Steul K; Juergens C; Ahlers N; Baker S; Jansen KU; Devlin C; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2010 Jun; 28(25):4192-203. PubMed ID: 20417262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological responses to pneumococcal vaccine in frail older people.
    Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
    Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.
    Brandão AP; de Oliveira TC; de Cunto Brandileone MC; Gonçalves JE; Yara TI; Simonsen V
    Vaccine; 2004 Dec; 23(6):762-8. PubMed ID: 15542200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Neuzil KM; Nahm MH; Whitney CG; Yu O; Nelson JC; Starkovich PT; Dunstan M; Carste B; Shay DK; Baggs J; Carlone GM
    Vaccine; 2007 May; 25(20):4029-37. PubMed ID: 17391816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
    Ortqvist A; Henckaerts I; Hedlund J; Poolman J
    Vaccine; 2007 Mar; 25(13):2445-50. PubMed ID: 17052816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.
    Frenck R; Thompson A; Yeh SH; London A; Sidhu MS; Patterson S; Gruber WC; Emini EA; Scott DA; Gurtman A;
    Pediatr Infect Dis J; 2011 Dec; 30(12):1086-91. PubMed ID: 21983216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.
    Ciprero K; Zykov KA; Briko NI; Shekar T; Sterling TM; Bitieva E; Stek JE; Musey L
    Hum Vaccin Immunother; 2016 Aug; 12(8):2142-2147. PubMed ID: 27149114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants.
    Grimprel E; Laudat F; Patterson S; Baker SA; Sidhu MS; Gruber WC; Emini EA; Scott DA
    Vaccine; 2011 Dec; 29(52):9675-83. PubMed ID: 22008822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants.
    Gattringer R; Winkler H; Roedler S; Jaksch P; Herkner H; Burgmann H
    Transpl Infect Dis; 2011 Oct; 13(5):540-4. PubMed ID: 21489090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
    Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
    Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants.
    Kim CH; Kim JS; Cha SH; Kim KN; Kim JD; Lee KY; Kim HM; Kim JH; Hyuk S; Hong JY; Park SE; Kim YK; Kim NH; Fanic A; Borys D; Ruiz-Guiñazù J; Moreira M; Schuerman L; Kim KH
    Pediatr Infect Dis J; 2011 Dec; 30(12):e235-43. PubMed ID: 21817957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
    Gadzinowski J; Albrecht P; Hasiec B; Konior R; Dziduch J; Witor A; Mellelieu T; Tansey SP; Jones T; Sarkozy D; Emini EA; Gruber WC; Scott DA
    Vaccine; 2011 Apr; 29(16):2947-55. PubMed ID: 21335032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
    Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
    J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population.
    Leach AJ; Morris PS; Mackenzie G; McDonnell J; Balloch A; Carapetis J; Tang M
    Vaccine; 2008 Jul; 26(31):3885-91. PubMed ID: 18562052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 13-valent pneumococcal conjugate vaccine.
    Prescrire Int; 2011 Jan; 20(112):5-7, 9. PubMed ID: 21462782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.
    Wysocki J; Tansey S; Brachet E; Baker S; Gruber W; Giardina P; Arora A
    Vaccine; 2010 Nov; 28(49):7779-86. PubMed ID: 20883736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.